Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Misses Estimates By $0.29 EPS

Spero Therapeutics (NASDAQ:SPRO) posted its earnings results on Thursday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.29), FiscalAI reports. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%.

Spero Therapeutics Stock Performance

Shares of Spero Therapeutics stock traded down $0.02 on Thursday, hitting $1.00. The stock had a trading volume of 328,412 shares, compared to its average volume of 331,374. The stock has a 50 day moving average of $1.14 and a 200 day moving average of $1.92. The firm has a market capitalization of $58.24 million, a P/E ratio of 9.27 and a beta of 1.59. Spero Therapeutics has a twelve month low of $0.96 and a twelve month high of $3.08.

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 40,851 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $1.04, for a total transaction of $42,485.04. Following the completion of the sale, the insider directly owned 946,000 shares in the company, valued at $983,840. This represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

SPRO has been the topic of a number of research analyst reports. HC Wainwright raised their price objective on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Monday, September 14th. Wall Street Zen cut shares of Spero Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Compass Point upgraded Spero Therapeutics to a “neutral” rating in a research note on Monday, September 14th. Weiss Ratings upgraded shares of Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. Finally, Cantor Fitzgerald started coverage on Spero Therapeutics in a research note on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Spero Therapeutics

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.